Andrew Blumenfeld, MD: Long-Term OnabotulimuntoxinA Use in the COMPEL Study
May 20th 2020The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.
Plasma P-Tau181 Biomarker May Be Accessible, Scalable Test for Alzheimer Disease
May 20th 2020Findings from an analysis of a large population of individuals suggest that the blood immunoassay can predict tau and amyloid-ß pathologies, as well as differentiate and identify Alzheimer disease across the clinical spectrum.
Amy Sullivan, PsyD, ABPP: Interdisciplinary Care in MS
May 20th 2020The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.
Ofatumumab Shines in Pooled Comparative Analysis in Relapsing Multiple Sclerosis
May 20th 2020The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.
Howard Fillit, MD: Aducanumab Findings Lead the Way in Dementia
May 20th 2020The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the landmark findings from Biogen on its agent aducanumab and the impact the trial might have on the future.
Analysis Suggests No Link Between OSA and Postoperative Delirium
May 20th 2020Contrary to prior literature, a new single-center analysis suggests that obstructive sleep apnea is not associated with delirium in those who were postoperatively admitted to the ICU, though PAP may reduce delirium in this patient population.
ADDF Diagnostic Accelerator Initiative Invests In Digital Memory Impairment Projects
May 17th 2020The Alzheimer’s Drug Discovery Foundation made 5 new investments through its Diagnostics Accelerator initiative, through which it has $50 million in commitments from leading scientific philanthropists such as Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Bezos.